Shares of Selecta Biosciences Inc (NASDAQ:SELB) have been assigned a consensus rating of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $8.40.
Several analysts recently issued reports on the company. Canaccord Genuity set a $40.00 target price on Mallinckrodt and gave the stock a “buy” rating in a research note on Monday, March 18th. Zacks Investment Research raised shares of General Moly from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.
SELB stock traded down $0.04 during midday trading on Thursday, reaching $1.67. 151,800 shares of the stock were exchanged, compared to its average volume of 479,650. The company has a market cap of $74.80 million, a PE ratio of -0.57 and a beta of 1.18. Selecta Biosciences has a 52 week low of $1.41 and a 52 week high of $16.55. The firm has a fifty day moving average of $1.96.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.06. The business had revenue of $0.01 million during the quarter. As a group, analysts anticipate that Selecta Biosciences will post -1.35 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of SELB. Wasatch Advisors Inc. grew its position in Selecta Biosciences by 2,546.1% in the first quarter. Wasatch Advisors Inc. now owns 2,923,702 shares of the company’s stock valued at $6,929,000 after acquiring an additional 2,813,212 shares in the last quarter. Polaris Venture Management Co. V L.L.C. grew its holdings in shares of Selecta Biosciences by 72.6% in the first quarter. Polaris Venture Management Co. V L.L.C. now owns 2,773,479 shares of the company’s stock valued at $6,573,000 after purchasing an additional 1,166,666 shares in the last quarter. Fosun International Ltd grew its holdings in shares of Selecta Biosciences by 153.4% in the first quarter. Fosun International Ltd now owns 438,330 shares of the company’s stock valued at $938,000 after purchasing an additional 265,330 shares in the last quarter. FMR LLC grew its holdings in shares of Selecta Biosciences by 23.5% in the fourth quarter. FMR LLC now owns 345,046 shares of the company’s stock valued at $918,000 after purchasing an additional 65,623 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Selecta Biosciences by 87.8% in the fourth quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock valued at $533,000 after purchasing an additional 93,719 shares in the last quarter. Institutional investors own 49.67% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.